Article in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
17 authors at 2 institutions in 1 country.
Daniel A GoldDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.ORCID 0009-0007-5092-1157
Pratik B SandesaraDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.ORCID 0000-0002-2809-8789
Vardhmaan JainDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.
Matthew E GoldDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.ORCID 0009-0007-1214-9469
Nishant VatsaDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.ORCID 0000-0001-5521-889X
Shivang R DesaiDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.ORCID 0000-0002-5577-8480
Malika Elhage HassanDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.ORCID 0000-0003-1829-9322
Chenyang YuanDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health Emory University Atlanta GA.
Yi-An KoDepartment of Biostatistics and Bioinformatics, Rollins School of Public Health Emory University Atlanta GA.ORCID 0000-0002-6543-9765
Ayman AlkhoderDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.ORCID 0000-0001-9437-1301
Kiran EjazDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.ORCID 0000-0002-5095-3606
Zain AlviDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.ORCID 0009-0001-2982-5925
Alireza RahbarDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.ORCID 0000-0003-2093-3273
Wissam A JaberDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.ORCID 0000-0003-1059-2436
William J NicholsonDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.
Arshed A QuyyumiDivision of Cardiology, Department of Medicine Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine Atlanta GA.ORCID 0000-0002-8166-679X
Emory University · USAbbott Fund · US
Funding
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and InterventionP01HL086773 · NHLBI · EMORY UNIVERSITY · PI ROBACK, JOHN D · 2008 to 2019
$17.9M
Translational Research Core - Engagement and Behavior ChangeP30DK111024 · NIDDK · EMORY UNIVERSITY · PI Mohammed Kumail Ali · 2016 to 2026
$13.4M
Spousal Influences on Subclinical and Clinical Vascular and Myocardial DiseaseP01HL154996 · NHLBI · EMORY UNIVERSITY · PI Kabayam M Venkat Narayan, ARSHED A QUYYUMI · 2022 to 2026
$13.4M
Neuro HPA Project 1U54AG062334 · NIA · EMORY UNIVERSITY · PI Cecile Delille Lahiri, Vasiliki Michopoulos · 2018 to 2026
$12.2M
Vascular Responses During Mental StressP01HL101398 · NHLBI · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 2010 to 2015
$11.0M
Mental Stress and Myocardial Ischemia after MI: Sex Differences, Mechanisms and PrognosisR01HL109413 · NHLBI · EMORY UNIVERSITY · PI VACCARINO, VIOLA · 2012 to 2023
$6.9M
Multidisciplinary Research Training to Reduce Inequities in Cardiovascular HealthT32HL130025 · NHLBI · EMORY UNIVERSITY · PI Tené T Lewis, Viola Vaccarino · 2016 to 2026
$6.4M
Metabolomics of subclinical and clinical cardiovascular diseaseP20HL113451 · NHLBI · EMORY UNIVERSITY · PI JONES, DEAN PAUL · 2012 to 2016
$4.3M
Granulocyte-Macrophage Colony Stimulated Factor (GM-CSF) in Peripheral Arterial DiseaseR33HL138657 · NHLBI · EMORY UNIVERSITY · PI QUYYUMI, ARSHED A · 2018 to 2021
$3.0M
Elucidating the role of the gut reservoir and inflammation in driving cardiovascular disease among persons living with HIVR01HL166004 · NHLBI · EMORY UNIVERSITY · PI GAVEGNANO, CHRISTINA, LAHIRI, CECILE DELILLE · 2022 to 2025
$3.0M
Human iPSC-derived endothelial cells as Vascular TherapeuticsR61HL154116 · NHLBI · EMORY UNIVERSITY · PI YOON, YOUNG-SUP · 2020 to 2021
Background The survival benefit of revascularization of chronic total occlusion (CTO) of the coronary arteries remains a subject of controversy. We measured high sensitivity troponin-I (hsTn-I) levels as an estimate of myocardial ischemia in patients with stable coronary artery disease, with the hypothesis that (1) patients with CTO have higher levels of hsTn-I than patients without CTO, (2) hsTn-I levels will predict adverse cardiovascular events in patients with CTO, and (3) patients with elevated hsTn-I levels will have a survival benefit from CTO revascularization. Methods and Results In 428 patients with stable coronary artery disease and CTO undergoing coronary angiography, adverse event rates were investigated. Cox proportional hazards models and Fine and Gray subdistribution hazard models were performed to determine the association between hsTn-I level and incident event rates in patients with CTO. HsTn-I levels were higher in patients with compared with those without CTO (median 6.7 versus 5.6 ng/L,
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
High Sensitivity Troponin Level and Benefits of Chronic Total Occlusion Revascularization. · full record | OpenQuestion